donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > BLUE bluebird bio > Company Executives
BLUE bluebird bio
6.340
+0.750+13.42%
Post Mkt Price
6.330
-0.01-0.16%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Andrew ObenshainDirector, President and Chief Executive Officer9.26M----48male05/02/2022
Mr. Jason F. Cole, Esq.Principal Accounting Officer, Principal Financial Officer, Chief Strategy and Financial Officer and Treasurer3.52M----49male08/04/2022
Mr. Thomas J. KlimaChief Commercial Officer2.28M----50male08/04/2022
Ms. Anne-Virginie EggimannChief Regulatory Officer------49female05/02/2022
Ms. Jessica WhittenVice President, Global Controller and Chief Accounting Officer------45female03/04/2022
Mr. Nick LeschlyDirector7.33M----49male05/02/2022
Mr. Mark VachonIndependent Director289.42K----63male05/02/2022
Dr. John O. AgwunobiIndependent Director271.97K----57male05/02/2022
Dr. Elisabeth Leiderman, M.D.Independent Director296.65K----45female05/02/2022
Ms. Najoh Tita-ReidIndependent Director292.90K----49female05/02/2022
Dr. Charlotte Jones-BurtonIndependent Director------48female05/02/2022
Company Overview More
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
CEO: Obenshain, Andrew
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...